IgGenix Announces Patent Granted by USPTO Covering the Generation of Allergen-specific Antibodies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--IgGenix, Inc., a pre-clinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, announced today that the United States Patent and Trademark Office (USPTO) has issued patent No. 11,613,569, which covers the generation of allergen-specific antibodies. This patent, licensed exclusively by IgGenix from CZ Biohub SF, LLC, serves as the foundation for IgGenix’s proprietary SEQ SIFTER™ platform and the development of antibody treatments that address allergic reactions.

The patent, entitled “Identifying human B cells expressing anti-allergen antibodies,” covers methods for generating human monoclonal antibodies (mAbs) that bind to an allergen. IgGenix applies these techniques as part of its cutting-edge single-cell transcriptomics workflow to isolate rare IgE-producing B cells from the blood of allergic individuals. Leveraging the exquisite capability of the human immune system to produce potent antibodies against an antigen, IgGenix then re-engineers these human IgE mAbs as IgG mAbs to block and even prevent allergic reactions. IgGenix’s preclinical work to date has demonstrated the potential to block key allergens mediating reactivity with potentially better safety and faster onset of action compared to allergen-oriented approaches.

“Allergies are a growing health concern worldwide, impacting over 100 million people in the U.S. alone, and are characterized by a misdirected immune response towards otherwise harmless proteins,” said Derek Croote, PhD, Co-Founder and Chief Technical Officer of IgGenix. “Currently, there is no cure for allergies, and while desensitization regimens, such as immunotherapy, have shown some clinical benefit, there is a need for a fast, safe, and effective intervention that can improve the quality of life of allergic individuals. The issuance of this patent further strengthens our intellectual property position and demonstrates our commitment to innovating in the field of allergy.”

About IgGenix
IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address severe allergies. Through our proprietary SEQ SIFTER^™ discovery platform, developed from foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, we isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most important epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across severe food and environmental allergies. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects millions of people living with severe allergies. For more information, visit www.IgGenix.com.